TABLE 3.
Changes in kidney function and DSA
| Pulse steroids/IVIG | Pulse steroids/IVIG/Rituximab | |||||||
|---|---|---|---|---|---|---|---|---|
| Variables | Baseline | Index biopsy | Surveillance biopsy | P a | Baseline | Index biopsy | Surveillance biopsy | P a |
| Kidney function | ||||||||
| Creatinine (mg/dL) | 1.6 ± 0.5 | 2 ± 0.7 | 2.2 ± 1 | 0.2 | 1.4 ± 0.4 | 1.6 ± 0.5 | 1.8 ± 0.4 | 0.08 |
| eGFR (mL/min) | 47 ± 16 | 36 ± 13 | 35 ± 14 | 0.7 | 51.5 ± 14 | 40 ± 12.5 | 42 ± 13 | 0.4 |
| UPC (g/g) | 0.6 ± 0.6 | 1.8 ± 1.4 | 1.7 ± 1.6 | 0.8 | 0.5 ± 0.4 | 1.3 ± 1.4 | 0.7 ± 0.8 | 0.02 |
| HLA DSA | ||||||||
| Class I DSA (MFI) | N/A | 2063 ± 6200 | 1215 ± 3402 | 0.4 | N/A | 1577 ± 1911 | 739 ± 1096 | 0.04 |
| Class II DSA (MFI) | 4034 ± 6930 | 3173 ± 7665 | 0.5 | 5386 ± 7896 | 2895 ± 7543 | 0.1 | ||
| Class I + II DSA (MFI) | 8237 ± 17 373 | 4327 ± 8707 | 0.2 | 5953 ± 12 216 | 3518 ± 14 473 | 0.3 | ||
aBetween index and surveillance biopsy.
DSA, donor-specific antibody; eGFR, estimated glomerular filtration rate; MFI, mean fluorescence intensity; N/A, not applicable; UPC, urine-protein creatinine ratio.